ABIONYX Pharma SA AI Stock Analysis
Want to see FR:ABNX full AI Analyst Report?
ABIONYX Pharma SA (ABNX) AI Stock Analysis
ABIONYX Pharma SA
(Paris:ABNX)
The overall score is very low, driven primarily by severe financial distress including declining revenue, negative margins, and a weakening balance sheet. Technical trends confirm persistent bearish momentum, and the negative P/E ratio underscores the lack of profitability. The company's high cash burn and need for future financing present significant risks.
ABIONYX Pharma SA (ABNX) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 67.95M
- Dividend Yield
- ―
- Average Volume (3M)
- 140.26K
- Price to Earnings (P/E)
- -7.0
- Beta (1Y)
- -0.17
- Revenue Growth
- -10.38%
- EPS Growth
- -72.05%
- Country
- France
- Employees
- 49
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ABIONYX Pharma SA Business Overview & Revenue Model
Company Description
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This...
How the Company Makes Money
ABIONYX Pharma SA primarily aims to generate revenue through the development and eventual commercialization (directly or via partners) of its drug candidates; however, specific, current revenue streams and amounts (e.g., product sales, licensing inco...
ABIONYX Pharma SA Financial Statement Overview
Summary
Financial health is weak. Revenue is declining, gross margin is critically low at 9.3%, and operating and net losses are widening. The balance sheet shows a sharp drop in equity and rising debt-to-equity to 0.89. While cash burn has modestly improved, the company continues to consume cash and will likely need additional funding.
Income Statement
12Very NegativeBalance Sheet
18Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.88M | 4.06M | 4.60M | 4.64M | 5.25M | 675.00K |
| Gross Profit | 209.00K | 376.00K | 844.00K | 618.00K | 636.00K | 259.00K |
| EBITDA | -5.85M | -5.70M | -5.27M | -4.53M | -4.01M | -7.42M |
| Net Income | -8.06M | -5.55M | -4.40M | -3.52M | -4.21M | -5.82M |
Balance Sheet | ||||||
| Total Assets | 36.54M | 12.86M | 13.45M | 14.83M | 15.82M | 21.83M |
| Cash, Cash Equivalents and Short-Term Investments | 26.87M | 3.52M | 3.23M | 4.10M | 4.05M | 7.93M |
| Total Debt | 15.18M | 3.81M | 3.10M | 3.39M | 4.01M | 4.96M |
| Total Liabilities | 20.86M | 8.60M | 6.03M | 6.91M | 8.65M | 11.15M |
| Stockholders Equity | 15.68M | 4.26M | 7.42M | 7.92M | 7.17M | 10.68M |
Cash Flow | ||||||
| Free Cash Flow | -3.41M | -3.17M | -3.60M | -3.83M | -3.53M | -6.86M |
| Operating Cash Flow | -3.28M | -2.93M | -3.60M | -3.70M | -3.36M | -6.69M |
| Investing Cash Flow | -94.00K | -205.00K | -100.00K | -130.00K | -175.00K | 1.34M |
| Financing Cash Flow | 26.87M | 3.42M | 2.80M | 3.89M | -194.00K | 3.97M |
ABIONYX Pharma SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABNX, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 1.65, and below the 200-day MA of 2.48, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.34 is Neutral, neither overbought nor oversold. The STOCH value of 28.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABNX.
ABIONYX Pharma SA Peers Comparison
Overall Rating
FR:ABNX42Neutral
FR:ALSEN41Neutral
FR:SIGHT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | EUR 67.95M | -7.02 | -80.82% | ― | -10.38% | -72.05% | |
| 41Neutral | EUR 80.64M | -1.83 | -54.15% | ― | ― | 6.26% | |
| 40Underperform | EUR 18.61M | -1.04 | 52.39% | ― | -610.31% | 43.88% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ABNX | ABIONYX Pharma SA | 1.57 | -2.55 | -61.90% | |
| FR:ALCOX | Nicox SA | 0.28 | -0.02 | -8.33% | |
| FR:SIGHT | GenSight Biologics | 0.08 | -0.03 | -27.62% | |
| FR:ALSEN | Sensorion SAS | 7.62 | -8.68 | -53.23% |
ABIONYX Pharma SA Corporate Events
ABIONYX Pharma Reports October Share and Voting Rights Data
ABIONYX Pharma is a next-generation biopharmaceutical company focused on sepsis and intensive care, developing apoA-I-based biotherapies and HDL vectors for immune-inflammatory disorders. Its pipeline addresses serious conditions with limited treatme...
ABIONYX Pharma Partners With CHU de Lille on CER-001 Sepsis Research
ABIONYX Pharma has signed a strategic partnership with CHU de Lille’s Burn Treatment Center and Intensive Care–Resuscitation Department to study apoA-I, functional HDL, endotoxin burden and immune-inflammatory dysregulation in severely burned and cri...
ABIONYX Pharma Secures Full CER-001 Manufacturing Chain with AXPLORA Partnership
ABIONYX Pharma has completed an end-to-end manufacturing chain for its flagship biopharmaceutical CER-001 by signing a strategic purification partnership with CDMO AXPLORA, adding to existing industrial agreements with TEXCELL and OLON. The collabora...
ABIONYX Taps OLON for Scalable Manufacturing of Complex Biologic CER-001
ABIONYX Pharma has entered a strategic manufacturing partnership with global CDMO OLON to advance CER-001, a complex biologic based on full-length recombinant human apoA-I assembled into biomimetic HDL particles. The deal positions OLON to handle ups...
ABIONYX Pharma Updates Voting Rights as It Advances Sepsis-Focused Biotherapies
ABIONYX Pharma, a biopharmaceutical company focused on sepsis and critical care, develops apoA-I-based biologics and HDL carriers to address immune-inflammatory dysregulation in severe diseases where effective treatments are lacking. Backed by strong...
ABIONYX Pharma trims bond debt with share-backed repayment, keeps cash runway to 2028
ABIONYX Pharma has partially repaid €1.75 million of its bond financing with Fenja Capital II A/S, settling about 70% in cash and 30% through a reserved capital increase of €0.52 million via the issuance of 331,299 new shares. The new shares, priced...
ABIONYX bolsters cash to €26.9m as losses deepen and sepsis strategy advances
ABIONYX Pharma reported first-half 2026 consolidated revenue of €1.9 million, generated entirely by its IRIS Pharma ophthalmology CRO unit, while its sepsis and LCAT deficiency programs remain pre-revenue and continue to supply bioproducts for Norum...
ABIONYX Pharma Taps TEXCELL to Advance Viral Safety and Industrialization of CER-001
ABIONYX Pharma has entered a strategic partnership with TEXCELL, a division of ABL Diagnostics, to conduct viral safety and clearance studies for CER-001 as it prepares validation batches of its bioproduction process in France. The work is central to...
ABIONYX Pharma Updates Share Capital and Voting Rights Structure
ABIONYX Pharma reported that as of August 31, 2026, its outstanding share capital stood at 43,736,415 shares, corresponding to 55,932,492 gross voting rights and 55,705,013 net voting rights. The disclosure, made in line with AMF regulations on votin...
ABIONYX Pharma Posts €1.9 Million H1 Revenue and Extends Cash Runway to 2028
ABIONYX Pharma reported consolidated half-year revenue of €1.9 million at the end of June 2026, entirely driven by its ophthalmology CRO unit IRIS Pharma, with biotech operations recording no sales as the company continues supplying its bioproduct fr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 18, 2026
